TIDMAGY
Allergy Therapeutics PLC
09 June 2023
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Allergy Therapeutics shares key scientific findings from
innovative research portfolio at Congress of the European Academy
of Allergy and Clinical Immunology (EAACI) 2023
9 June 2023 Allergy Therapeutics (AIM: AGY), the fully
integrated specialty pharmaceutical company specialising in allergy
immunotherapy, today announces that the Group will be sharing key
scientific findings from across its research portfolio at the
upcoming European Academy of Allergy and Clinical Immunology
(EAACI) Hybrid Congress, taking place from today until 11 June 2023
in Hamburg, Germany.
The EAACI Congress is the world's largest scientific conference
specialising in the field of allergy and clinical immunology and
the flagship meeting of the European Academy of Allergy and
Clinical Immunology, an association of more than 12,000 clinicians,
researchers, and allied health professionals, dedicated to
improving the health of people affected by allergic diseases.
Among its nine posters being presented, Allergy Therapeutics
will share:
-- Further clinical and preclinical studies on biomarker
strategies, patient responses and the mechanism of action of
allergy immunotherapies. Part of the data is derived from the
positive G309 exploratory field study which evaluated the efficacy
and safety of Grass MATA MPL, the Group's short-course subcutaneous
allergen-specific immunotherapy (SCIT) candidate to address the
cause of symptoms of allergic rhinoconjunctivitis due to grass
pollen. These findings supported the design of the ongoing pivotal
Phase III Grass MATA MPL G306 trial, which is on track to report
interim topline safety & efficacy data in Q4 2023.
-- Further pre-clinical data characterising the mechanism of
action of the Group's novel virus-like particle (VLP) based peanut
allergy vaccine candidate ("VLP Peanut"), which is currently being
investigated in the Phase I PROTECT trial with plans on track for
data later in 2023.
-- Preclinical studies examining allergenic venom homology, an
area in which the Group is currently commercially active.
Allergy Therapeutics will also be hosting a hybrid symposium,
"SCIT; pioneering a new era", on Saturday 10 June, 14:30-15:30
CEST, chaired by Professor Dr. med. Ludger Klimek, Head of the
Centre for Rhinology and Allergology, Wiesbaden, Germany. The
symposium will consist of three presentations covering the topics
of venom immunotherapy, biomarker strategies in allergy
immunotherapy and an analysis of the VLP Peanut PROTECT study,
further exploring how the trial's study design bridges the
pre-clinical and clinical boundaries.
Results from the completed G309 exploratory field trial,
investigating Grass MATA MPL, the Group's short-course subcutaneous
allergen-specific immunotherapy (SCIT) candidate, have been
accepted for upcoming publication in the official journal of the
EAACI, Allergy. During the EAACI congress on Sunday 11 June at
15:00 - 15:30 CEST, Professor Mohamed Shamji, Reader in Immunology
& Allergy at Imperial College London, will give an overview of
this recently accepted publication titled "Short-course
subcutaneous pre-seasonal treatment with a 13-grass pollen
allergoid reduces allergy symptoms and relief medication use in
allergic rhinitis: A randomised, double-blind, placebo-controlled
adaptive trial ". This session will be in Hall Y 7 on Level 2
during the SY 19 - Cutting Edge in Allergy, Asthma and Immunology
session.
Manuel Llobet, Chief Executive Officer at Allergy Therapeutics,
commented : "We are excited to be participating in this year's
EAACI congress, joining like-minded scientists and industry
professionals, united in one mission - to improve the lives of
people living with allergies. With two innovative short-course
allergy immunotherapies currently in the clinic, Allergy
Therapeutics is delivering on its commitment to develop the next
generation of allergy immunotherapies with the potential to
transform patients' lives. The Phase III trial of our short-course
grass pollen immunotherapy candidate, Grass MATA MPL, and the Phase
I PROTECT trial of our peanut allergy vaccine candidate, VLP
Peanut, are currently underway and we are looking forward to
sharing further insights with the community on these potentially
transformative allergy therapies. "
The complete list of Allergy Therapeutics-sponsored abstracts
accepted by EAACI for presentation are available on the Group's
website.
No new material price sensitive information is expected to be
disclosed on Allergy Therapeutics at the EAACI Congress 2023.
Allergy Therapeutics' Hybrid Symposium
SCIT; pioneering a new era
Saturday 10 June 2023; 14:30-15:30 (CEST)
Introduction Introduction
Chair: Professor Dr. med. Ludger
Klimek, Head of the Centre for
Rhinology and Allergology, Wiesbaden,
Germany
-------------------------------------
Speaker Venom Immunotherapy: Efficacy
Dr. Arantza Vega Castro, Chief led by quality
of the Allergy Department - Guadalajara
University Hospital. Associated
Professor - International University
of Catalonia. Chair of the EAACI
insect venom hypersensitivity working
group
-------------------------------------
Speaker: Biomarker Strategies in AIT:
Dr. Janice A Layhadi, Immunomodulation A primer for the practitioner
and Tolerance Group, Allergy and
Clinical Immunology, Department
of National Heart and Lung Institute,
Imperial College London, London,
UK
-------------------------------------
Speaker: VLP Peanut PROTECT Study: bridging
Prof. Dr. Martin Bachmann, Head the preclinical-clinical boundaries
of the Department of Immunology,
University of Bern, Switzerland
and Professor of Immunology, University
of Oxford, Nuffield Department
of Medicine
-------------------------------------
All speakers Q&A
-------------------------------------
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Martin Hopcroft, Interim Chief Financial Officer
Panmure Gordon (Nominated Adviser and Broker)
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company, headquartered in the UK, focussed on the
treatment and diagnosis of allergic disorders, including aluminium
free immunotherapy vaccines that have the potential to cure
disease. The Group sells proprietary and third-party products from
its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad
pipeline of products in clinical development includes vaccines for
grass, tree, house dust mite and peanut. For more information,
please see www.allergytherapeutics.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAPKPESPDEFA
(END) Dow Jones Newswires
June 09, 2023 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Allergy Therapeutics (LSE:AGY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
